| |  Online-Ressource |
|---|
| Verfasst von: | Xu, Qiang [VerfasserIn]  |
|---|
| | Huang, Xuemei [VerfasserIn] |
|---|
| | Meng, Zenghui [VerfasserIn] |
|---|
| | Li, Yingrui [VerfasserIn] |
|---|
| | Zhong, Rujia [VerfasserIn] |
|---|
| | Li, Xin [VerfasserIn] |
|---|
| | Cyganek, Lukas [VerfasserIn] |
|---|
| | El-Battrawy, Ibrahim [VerfasserIn] |
|---|
| | Akın, Ibrahim [VerfasserIn] |
|---|
| | Zhou, Xiao-Bo [VerfasserIn] |
|---|
| | Lan, Huan [VerfasserIn] |
|---|
| Titel: | Antiarrhythmic effects of vernakalant in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1 |
|---|
| Verf.angabe: | Qiang Xu, Xuemei Huang, Zenghui Meng, Yingrui Li, Rujia Zhong, Xin Li, Lukas Cyganek, Ibrahim El-Battrawy, Ibrahim Akin, Xiaobo Zhou and Huan Lan |
|---|
| E-Jahr: | 2022 |
|---|
| Jahr: | 9 April 2022 |
|---|
| Umfang: | 14 S. |
|---|
| Fussnoten: | Gesehen am 02.04.2024 |
|---|
| Weitere Titel: | Titel des übergeordneten Special issues: Takotsubo syndrome, Short QT syndrome and Brugada syndrome |
|---|
| Titel Quelle: | Enthalten in: Journal of cardiovascular development and disease |
|---|
| Ort Quelle: | Basel : MDPI AG, 2014 |
|---|
| Jahr Quelle: | 2022 |
|---|
| Band/Heft Quelle: | 9(2022), 4, Artikel-ID 112, Seite 1-14 |
|---|
| ISSN Quelle: | 2308-3425 |
|---|
| Abstract: | (1) Background: Short QT syndrome (SQTS) may result in sudden cardiac death. So far, no drugs, except quinidine, have been demonstrated to be effective in some patients with SQTS type 1 (SQTS1). This study was designed to examine the potential effectiveness of vernakalant for treating SQTS1 patients, using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from a patient with SQTS1. (2) Methods: Patch clamp and calcium imaging techniques were used to examine the drug effects. (3) Results: Vernakalant prolonged the action potential duration (APD) in hiPSC-CMs from a SQTS1-patient (SQTS1-hiPSC-CMs). In spontaneously beating SQTS1-hiPSC-CMs, vernakalant reduced the arrhythmia-like events induced by carbachol plus epinephrine. Vernakalant failed to suppress the hERG channel currents but reduced the outward small-conductance calcium-activated potassium channel current. In addition, it enhanced Na/Ca exchanger currents and late sodium currents, in agreement with its APD-prolonging effect. (4) Conclusions: The results demonstrated that vernakalant can prolong APD and reduce arrhythmia-like events in SQTS1-hiPSC-CMs and may be a candidate drug for treating arrhythmias in SQTS1-patients. |
|---|
| DOI: | doi:10.3390/jcdd9040112 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/jcdd9040112 |
|---|
| | kostenfrei: Volltext: https://www.mdpi.com/2308-3425/9/4/112 |
|---|
| | DOI: https://doi.org/10.3390/jcdd9040112 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| Sach-SW: | antiarrhythmic drugs |
|---|
| | arrhythmias |
|---|
| | human-induced pluripotent stem cell-derived cardiomyocytes |
|---|
| | short QT syndrome |
|---|
| | vernakalant |
|---|
| K10plus-PPN: | 1884691048 |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Antiarrhythmic effects of vernakalant in human-induced pluripotent stem cell-derived cardiomyocytes from a patient with short QT syndrome type 1 / Xu, Qiang [VerfasserIn]; 9 April 2022 (Online-Ressource)
